Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07325136 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer
A Phase 1 study of Relapsed/Refractory Small Cell Lung Cancer, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 240
- Enrollment target
- 11
- Study locations
NCT07325136: Recruiting Phase 1 study of Relapsed/Refractory Small Cell Lung Cancer, sponsored by Bristol-Myers Squibb.
NCT07325136 is a Phase 1 study of Relapsed/Refractory Small Cell Lung Cancer that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 240 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (300% higher). The trial reports 11 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07325136, a Phase 1 study of Relapsed/Refractory Small Cell Lung Cancer, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 240 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of this study is to assess the safety and tolerability of BMS-986525 alone and in combination with Nivolumab in participants with Relapsed/Refractory Small Cell Lung Cancer
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG BMS-986525
Study Locations (11)
Other
- Local Institution - 0003 - Craiova
- Local Institution - 0009 - Madrid
Michigan
- Local Institution - 0011 - Detroit
New York
- Local Institution - 0026 - Buffalo
North Carolina
- Local Institution - 0005 - Durham
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
Tennessee
- SCRI Oncology Partners - Nashville
Milano
- Local Institution - 0001 - Rozzano
Osaka
- Local Institution - 0020 - Hirakata
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2026-02-03 |
| Est. Completion | 2029-04-24 |
| Phase | Phase 1 |
What NCT07325136 shows while recruiting
NCT07325136 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (300% higher).
The record links to 1 condition, with Relapsed/Refractory Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT07325136 lists 11 locations in 10 states (Other, Michigan, New York).
Frequently Asked Questions
What is clinical trial NCT07325136 about?
NCT07325136 is a clinical study titled "A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer". The purpose of this study is to assess the safety and tolerability of BMS-986525 alone and in combination with Nivolumab in participants with Relapsed/Refractory Small Cell Lung Cancer
What is the current status of trial NCT07325136?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 240 participants. The study started on 2026-02-03. Estimated completion is 2029-04-24.
What conditions does trial NCT07325136 study?
This clinical trial studies the following conditions: Relapsed/Refractory Small Cell Lung Cancer.
What interventions are being tested in trial NCT07325136?
The interventions under investigation include: Nivolumab (DRUG), BMS-986525 (DRUG).
Who is sponsoring clinical trial NCT07325136?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07325136 being conducted?
This trial has 11 study locations across Michigan, New York, North Carolina, Ohio, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed/Refractory Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07325136's enrollment target sits among peer trials
240 197th of 2000 higher than 1,789 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI